Co-Diagnostics and CoSara Raise HPV Awareness
The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day.
SALT LAKE CITY, March 3, 2025 — Co-Diagnostics, Inc. (NASDAQ: CODX), a leading molecular diagnostics firm known for its innovative platform for creating tests, has announced a significant event in collaboration with CoSara Diagnostics Pvt. Ltd. This symposium will celebrate International HPV Awareness Day, highlighting the pressing issues surrounding HPV and cancer.
Entitled "HPV and Cancer: Exploring Advances in Prevention and Care," this one-day event will dedicate itself to education and awareness efforts regarding HPV. The symposium will feature speakers from both Co-Diagnostics and CoSara, alongside noted experts in oncology and cancer diagnostics. This gathering aims to share insights and advancements across the scientific community.
International HPV Awareness Day, recognized each year on March 4, serves as a platform to inform the public about human papillomavirus (HPV), aiming to reduce the stigma associated with the virus and encouraging proactive measures to minimize its impact.
According to the National Cancer Institute, high-risk HPV subtypes are responsible for causing roughly 5% of all cancers around the globe. This alarming statistic emphasizes the need for increased awareness, as evidenced by the reported cervical cancer fatalities which amounted to an estimated 350,000 deaths in 2022. In many cases, these tragedies occur predominantly in low- and middle-income countries (LMICs), underlining the urgent requirement for accessible diagnostics, effective vaccinations, and comprehensive cancer screenings.
This symposium coincides with Co-Diagnostics' progress on their HPV multiplex test. This innovative test is developed on the Co-Dx PCR point-of-care platform and is set for pre-clinical studies. The test aims to provide reliable and affordable HPV screening solutions worldwide, particularly benefiting patients in LMICs.
"The early detection of illnesses is crucial for effective treatment and encouraging regular health check-ups among patients. This is essential not only for limiting the spread of HPV but also for the overall health of communities," stated Dwight Egan, CEO of Co-Diagnostics. He expressed optimism about their HPV multiplex test and reflected on the commitment to raising awareness through this symposium.
Mohal Sarabhai, CEO of CoSara, shared their commitment to enhancing access to high-quality diagnostics, saying, "Providing a forum for leaders in HPV research and cancer care fosters a culture of sharing knowledge, which is essential for advancing disease prevention and overall global health."
CoSara's Saragene® Human Papillomavirus-High Risk real-time PCR test has received clearance from the Indian CDSCO for use in clinical laboratories, allowing for the detection of high-risk HPV genotypes.
*The Co-Dx PCR platform is subject to regulatory review and is not currently available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., based in Utah, is at the forefront of molecular diagnostics, developing cutting-edge technologies that significantly enhance healthcare. The company focuses on tests designed for the detection and analysis of nucleic acids (DNA or RNA), and is dedicated to producing specific tests for its Co-Dx PCR platform to identify genetic markers in various health applications.
Frequently Asked Questions
What is the purpose of the symposium hosted by Co-Diagnostics and CoSara?
The symposium aims to raise awareness about HPV and cancer, featuring discussions on recent advances in prevention and care.
When is the symposium scheduled to take place?
The event is set for March 4, which is recognized as International HPV Awareness Day.
Who will be speaking at the symposium?
Speakers will include representatives from Co-Diagnostics, CoSara, and experts in oncology from around the region.
What specific test is Co-Diagnostics developing related to HPV?
Co-Diagnostics is working on an HPV multiplex test aimed at improving screening capabilities for high-risk HPV subtypes.
How does HPV contribute to cancer risk?
High-risk HPV subtypes are known to cause approximately 5% of all cancers globally, particularly impacting cervical cancer rates.
